Reference
Boone NW, et al. Less is more: a cost benefit analysis of a changed posology for nivolumab. European Journal of Clinical Pharmacology : 28 Jan 2020. Available from: URL: http://doi.org/10.1007/s00228-020-02839-7
Rights and permissions
About this article
Cite this article
Fixed dosage regimen of nivolimab increases costs. PharmacoEcon Outcomes News 846, 14 (2020). https://doi.org/10.1007/s40274-020-6553-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6553-7